

# Contents

---

---

## SECTION 1: CLINICAL CARDIOLOGY

---

---

- 1. Development of Cardiology in India: Are We on the Right Track? \_\_\_\_\_ 3**  
*Padmavati S*  
Cardiac Society and Foundation 3  
Funding of Health Care 3  
Preventive Programs 3  
Research 4  
Lack of International Recognition 4
- 2. History of Thrombolysis \_\_\_\_\_ 5**  
*Chopra HK, Sambi RS, Krishna CK*  
Development of Thrombolytic Therapy 5  
Advantages of Newer Agents Over the Older Agents 8  
Trends in Thrombolysis 8
- 3. Epicardial Reperfusion \_\_\_\_\_ 10**  
*Chopra HK, Sambi RS, Krishna CK*  
Importance of Epicardial Reperfusion 10  
No-Reflow Phenomenon 10  
Measures of Epicardial Reperfusion 11  
Reperfusion Strategies 12
- 4. History of Beta-Blockers \_\_\_\_\_ 15**  
*Cruickshank JM*  
The Very Early Days 15  
The Pharmacology and Adverse Reactions of Different  $\beta$ -Blockers 15  
Coronary Artery Disease; Peripheral Arterial Disease; Arrhythmias; The Atheromatous Process 21  
Beta-Blockers in Hypertension 23  
Beta-Blockers and Heart Failure 26  
Other Indications 28
- 5. History of Antithrombotics Agents \_\_\_\_\_ 31**  
*Jariwala P, Chandra KS*  
Antiplatelet Agents 31  
Anticoagulants 38  
Thrombolytic Agents 45
- 6. History of Statins \_\_\_\_\_ 49**  
*Manchanda SC, Makhija A, Sharma MK*  
The Discovery of Compactin—Initial Molecule 49  
Mechanism of Action 50  
Pharmacology 50  
Adverse Effects and Drug Interactions 50  
Safety Results 52  
Current Indications of Statins 52  
Statin Trials—Primary Prevention 52  
Statin Trials—Stable Coronary Heart Disease 55

Statin Trials—Acute Coronary Syndromes	55
Utility of Statins in Special Populations	56
Statins in Combination with Other Lipid-Lowering Drugs	56
Which Statin and What Dose to Start with—Indian Scenario	56
Future Directions	57
<b>7. History of Angiotensin Receptor Blockers</b>	<b>59</b>
<i>Pancholia AK, Jain V, Tewari S</i>	
The Angiotensin II Receptor	59
Functions beyond Hypertension Control	60
The Renin-Angiotensin Cascade and Angiotensin II Receptor Subtypes	61
Development of Saralasin	61
Development from Losartan to Other Drugs	62
The ARB Controversy—Myocardial Infarction	62
Cardiovascular Protection—A Breakthrough for High-Risk Patients	62
The New Challenge—ARBs as a Cancer Risk Factor	65
Time Line of Landmark Trials with ARBs	65
ARBs Under Development	65
Selected Abbreviations and Acronyms	65
<b>8. History of Heparin and Cardiovascular Disease Protection</b>	<b>68</b>
<i>Banerjee AK, Ray S</i>	
Early Days	68
Research Escalates	68
Heparin in Clinical Domain	69
Postwar Resurrection	69
Procreation	70
Heparin in Cardiovascular Disease	70
Sibling Rivalry	71
Epilogue	71
<b>9. History of ACE-Inhibitors</b>	<b>73</b>
<i>Sawhney JPS</i>	
<b>10. Antibiotics in Cardiology</b>	<b>76</b>
<i>Sharma KB</i>	
Emerging Relationships of Infections and the Cardiovascular System	76
Cardiovascular Infections	76
Acute Rheumatic Fever	76
Infective Endocarditis	77
<b>11. Polypill in Cardiovascular Disease: Current Evidence and Future Promises</b>	<b>80</b>
<i>Kuppuswamy V, Choo WK, Gupta S</i>	
Current Strategies in Reducing Cardiovascular Risk	80
The Birth of Polypill	80
Failure of Current Preventive Strategies	81
Components of a Polypill	82
Polypill in Primary Prevention	85
Polypill in Secondary Prevention	85
Limitations of the Polypill	85
<b>12. The History of Acute Coronary Syndrome</b>	<b>87</b>
<i>Bansal M, Mehrotra R, Kasliwal RR</i>	
Anatomy and Physiology of Circulation	87
Understanding the Pathophysiology of Acute Coronary Syndrome	88

Evaluation of Acute Coronary Syndrome	89
Management of Acute Coronary Syndrome	90
<b>13. History of AMI: A Saga of Transition from Tortoise Walks to Rabbit Run</b>	<b>92</b>
<i>Chouhan NS, Chandra P</i>	
Stethoscope Era	92
Era of Electrocardiography	93
Concept of Coronary Care Units	95
Pharmacotherapy Era	95
Reperfusion Era	95
Primary Angioplasty Era	96
The Platelet Inhibitors	96
Stenting Era	96
<b>14. History of Nitrates</b>	<b>99</b>
<i>Gupta R, Mangla S, Bhatnagar A, Chopra HK, Parashar SK</i>	
History	99
Wartime Production Rates	99
Instability and Desensitization	100
Detonation	100
Manufacturing	100
Use as an Explosive and a Propellant	100
Nitroglycerin and Dynamite	101
Industrial Exposure	102
<b>15. History of Calcium Channel Blockers</b>	<b>103</b>
<i>Guha S, Mukherjee S, Karmakar RN</i>	
<b>16. Antiplatelet Therapy—History and Future Trends, with Special Reference to Prasugrel</b>	<b>107</b>
<i>Singh M, Sharma V, Singh A</i>	
Historic Milestones in Antiplatelet Therapy	107
Classification of Antiplatelet Drugs	107
Pathophysiology of Atherothrombosis—Role of Platelets	107
Antiplatelet Therapy	109
ADP Receptor Blockers—Thienopyridines	109
Glycoprotein IIA/IIIB Receptor Blockers	110
Novel Drugs—Special Reference to Prasugrel	110
Prasugrel	110
Future Trends	111
<b>17. History of Antiarrhythmic Drugs</b>	<b>113</b>
<i>Wander GS, Kaushal S</i>	
Quinidine	113
Procainamide	113
Lidocaine	114
Phenytoin	114
Sparteine	114
Ajmaline	115
Moricizine	115
Bretylium	115
Amiodarone	115
Flecainide and Others	115
β-Blockers	116
Calcium Blockers	116

Atropine and Others	116
Classification	117
Recent Studies	117
<b>18. Enhanced External Counterpulsation and Its Clinical Applications</b>	<b>120</b>
<i>Chopra HK, Krishna CK, Sambhi RS, Aggarwal KK, Parashar SK, Manjuran RJ, Gupta R, Bansal M, Kasliwal RR, Mittal S, Srivastava S, Nanda NC</i>	
Historical Background and Development	120
Researchers in the 1970s and Late 1980s	121
What is the Principle of Mechanism?	127
Enhanced External Counterpulsation	127
What are the Effects of EECp?	128
What are the Indications?	128
What are the Contraindications?	128
<b>19. Lycopene and Related Tomato Carotenoids in Coronary Heart Disease</b>	<b>130</b>
<i>Henkin Y</i>	
Bioavailability and Absorption of Lycopene	130
Role of Oxidation in the Pathogenesis of Coronary Heart Disease	131
Antioxidant Properties of Lycopene	131
Additional Potential Mechanisms for Inhibition of Atherosclerosis by Lycopene	131
Epidemiological Studies	132
<b>20. History of Oils, Fats and Coronary Heart Disease</b>	<b>135</b>
<i>Jain P</i>	
The Beginnings	135
Protein Toxicity Versus Lipid Hypothesis	135
Observations in Familial Hypercholesterolemia	135
Diet and the Heart	136
A Note on the Saga of Trans-Fats	138
<b>21. History of Cardiac Fitness</b>	<b>140</b>
<i>Somasundaram M, Raghothaman S</i>	
History of Cardiac Fitness Programs	140
Rehabilitation/Maintaining Fitness after Discharge	142
Aerobics for Cardiac Fitness—Its History	143
Other Advantages of a Fit Lifestyle—History of Its Discovery	144
<b>22. History of Blood Pressure and Its Measurement</b>	<b>147</b>
<i>Hegde BM</i>	
The Beginning	147
Later Developments	148
What is The Future?	148
<b>23. History of Blood Pressure Amplification between the Heart and Peripheral Arteries</b>	<b>149</b>
<i>Rourke MO, Adjani A, Namasivayam M</i>	
<b>24. The History of Cardiac Rehabilitation: An Evolutionary Perspective</b>	<b>156</b>
<i>Sahgal V</i>	
Prehistoric	156
Modern Times	157
<b>25. A Brief Historical Chronicle of Hypertension</b>	<b>160</b>
<i>C Venkata S Ram</i>	
Systemic Hypertension as a Risk Factor for the Global Disease Burden	160
Hypertension and Target Organ Damage	160
History of Blood Pressure Measurement	162

Reducing the Burden of Cardiovascular Disease	163
History of Anti-Hypertensive Drugs—From Reserpine to Aliskiren	163
<b>26. History of Risk Factor Stratification of Hypertension</b>	<b>168</b>
<i>Mehta NP, Shah SN</i>	
United States Guidelines (1977–2003)	168
Indian Hypertension Guidelines (2001–2007)	171
World Health Organization/International Society of Hypertension Guidelines (1986–2003)	173
European Society of Hypertension (ESH) and European Society of Cardiology (ESC) Guidelines—(2003–2007)	176
British Hypertension Society Guidelines (1989–2004)	178
<b>27. Retracing the Heroic Steps from Lipid Hypothesis to Aggressive Treatment of Blood Cholesterol—A Revolution in Preventive Cardiology</b>	<b>180</b>
<i>Enas EA, Kuruwila AT, Lulla S</i>	
Atherosclerotic Cardiovascular Disease	180
Cardiovascular Epidemic and Cholesterol Wars	180
Nicholai N Anitschkow—The Father of Atherosclerosis	180
The Lipid Hypothesis	182
Genetic Evidence of High Cholesterol Producing Heart Attacks in Children	182
Familial Hypercholesterolemia	182
Goldstein Brown and LDL Receptor	182
Cholesterol-Year Score and Coronary Atherosclerosis	183
John Gofman—The Father of Clinical Lipidology	183
LDL-C and Lipoproteins	183
Oxidized LDL	184
Low HDL—The Body Armor against Atherosclerosis	184
Lipoprotein (A)—A Dangerous Genetic Variant of LDL	184
Donald Fredrickson and Classification of Lipoproteins	184
How High is High Blood Cholesterol?	184
Ancel Keys and International Comparison of Cholesterol Levels	185
The Framingham Heart Study—The Mother of All Epidemiological Studies	185
Diet-Heart Disease Versus Diet-Blood Cholesterol-Heart Disease Paradigm	185
Impact of Dietary Cholesterol on Blood Cholesterol	185
Cholesterol Agnostics	186
Dietary Intervention Trials	186
Dramatic Reduction in Blood Cholesterol with Intestinal Bypass Surgery	187
How to Lower the Blood Cholesterol?	188
Jeremiah Stamler and American Heart Association (AHA)	188
Lipid Research Clinics	189
LRC-CPPT (Coronary Primary Prevention Trial)	189
The 1984 NIH Consensus Development Conference	190
The National Cholesterol Education Program	190
Akira Endo and the Era of Statins—The Underused Wonder Drugs	190
Statin Mega Trials and Revolution in Preventive Cardiology	191
Blood Cholesterol, Stroke and Statins	191
How Safe are Statins?	191
How Low is Low LDL-C?	191
Does Low Cholesterol Increase Non-CVD Mortality?	192
When to Start LDL-C Lowering Therapy?	192
<b>28. Past, Present and Future of Cardiovascular Dysmetabolic Syndrome</b>	<b>195</b>
<i>Srikanth S, Deedwania P</i>	
Historical Perspective	195

Evolution of the Definition 195  
 Prevalence 196  
 Clinical Implications 197  
 Understanding Pathophysiology of CDS 197  
 Identification 199  
 Therapy 200  
 Lifestyle Modification 200  
 Pharmacological Options 201  
 Surgical Management 205  
 Current Controversies and Future Direction 205

- 29. History of Obesity and Cardiovascular Disorder** \_\_\_\_\_ **209**  
*Manoria PC, Pankaj M, Verma RK, Manoria P*  
 Obesity and Relation with Various Diseases 209  
 Different Body Shapes and Obesity Risk 209  
 Obesity and Syndrome X 210  
 Treatment of Obesity in the Early Days 210  
 The Situation Today 210
- 30. History of Dilated Cardiomyopathy** \_\_\_\_\_ **211**  
*Bahl A, Nahar U, Talwar KK*  
 Dilated Cardiomyopathy 211  
 The Genetics of Dilated Cardiomyopathy 212  
 Treatment 212
- 31. History of Hypertrophic Cardiomyopathy** \_\_\_\_\_ **215**  
*Parakh N, Bhargava B*  
 The First Citation 215  
 History before History 216  
 The Journey after Teare 216  
 The First Surgery 216  
 Journey to Golden Jubilee 216
- 32. History of Restrictive Cardiomyopathy** \_\_\_\_\_ **219**  
*Venugopal K*  
 The Enigma of Endomyocardial Fibrosis 219  
 Geographical Distribution 219  
 History of Endomyocardial Fibrosis 219  
 Endomyocardial Fibrosis in India 220  
 Cardiac Amyloidosis 220  
 Other Infiltrative and Storage Disorders 221
- 33. Peripartum Cardiomyopathy** \_\_\_\_\_ **224**  
*Deshpande NV*  
 Epidemiology 224  
 Etiology and Pathogenesis 224  
 Clinical Presentation 225  
 Management 225  
 Natural History and Prognosis 226
- 34. History and Clinical Implications of Myocarditis and Pericarditis** \_\_\_\_\_ **229**  
*Tewari S, Jain V, Pancholia AK*  
 Myocardium 229  
 Myocarditis 229  
 Etiology 229

Pathogenesis	230
Clinical Presentation	231
Diagnostic Evaluation	231
Natural History and Prognosis	232
Treatment	232
Future Directions	233
Pericarditis	233
Pericardial Effusion	234
Laboratory Investigations	235
<b>35. History of Infective Endocarditis and Future Directions</b>	<b>238</b>
<i>Sankardas MA, Subban VK</i>	
Historical Perspective	238
Pathophysiology of Endocarditis—Infectious or Inflammatory	239
Birth of Blood Culture	239
Experimental Reproduction of Endocarditis	240
Classification of Endocarditis	240
Antibiotic Era	241
Antibiotic Prophylaxis	241
Echocardiography and Infective Endocarditis	241
Diagnostic Criteria	241
Current Trends and Future Challenges	241
New Developments	242
<b>36. The History of Deep Vein Thrombosis and Pulmonary Thromboembolism</b>	<b>244</b>
<i>Deb PK, Chatterjee A</i>	
Etiology	244
Clinical Picture	245
Investigations	245
Medical Management	246
Surgical Management	247
Prevention	247
Epilogue	247
<b>37. Lessons Learnt from History of Rheumatic Heart Diseases</b>	<b>249</b>
<i>Vijayalakshmi IB</i>	
History in the 18th Century	249
History in the 19th Century	249
Rheumatism's New Face	251
Death From Acute Rheumatism: A New Outcome	251
Wells and "Rheumatism of the Heart"	252
Acute Rheumatism Changes again with Chorea	253
Patients and Doctors	253
Social Setting of Acute Rheumatism	255
Therapy for Rheumatism in the Early 19th Century	255
History of Drugs in Acute Rheumatic Fever	256
Treatment for Congestive Heart Failure	257
History in the 20th Century	257
Molecular Biology	258
Adrenocorticotrophic Hormone and Cortisone	258
Penicillin	259
Inadequacy of Public Health Programs	261
Sorting Out Therapy	262

- Variation of Virulence of Strains in a Single M Type 263  
 The Return of Rheumatic Fever and Invasive Gas Disease 264  
 Experimental Studies of the Capsule's Relation to Adherence, Epithelial Internalization, Colonization and Mucosal Invasion 264  
 Surgery for Rheumatic Fever 264

### 38. History of Pediatric Cardiology: From the "Untouchable" Heart to the Brave New Era \_\_\_\_\_ 270

- Maheshwari S, Kiran VS*  
 Legacy of a Young Branch 270  
 Prehistoric Era—Babylonian Clay Tablets 270  
 The Contributions from Greece—Galen 270  
 Renaissance Period—Leonardo Da Vinci 270  
 European Contribution—Steno and Tetralogy 271  
 Masterpiece Work—Morgagni 271  
 Account of a Blue Boy—Sandifort 271  
 Cyanotic Spells—Hunter 272  
 The Debate on Cyanosis—19th Century Europe 272  
 Works of a Seer—Sir Thomas Beville Peacock 273  
 Cardiac Septal Defects—Rokitansky 273  
 Tetralogy Defined—Fallot 273  
 The Godmother Arrived 274  
 Mother of Pediatric Cardiology 274  
 Tombstone of Paget's Views 275  
 Surgical Victory over the Arterial Duct—Robert Gross 275  
 New Ideas, New Directions 275  
 Success of Teamwork—Alfred Blalock and Vivien Thomas 276  
 Lateral Thinking—Other Paths for Tetralogy of Fallot Palliation 277  
 Structuring Pediatric Cardiology—Fellowship Programs 277  
 New Angles to Diagnosis—Catheterization Techniques 277  
 Conquering Valvular Lesions—Percutaneous Techniques 278  
 Devising the Devices—The Amplatzer Era 278  
 From No One's Child to A World Class Entity—Progress to World Congress 278  
 Dreams of Correction—Evolution of Definitive Surgery 278  
 Heart-Lung Machine—Saga of Gibbon 279  
 Story of a Single Pump—Glenn and Fontan 279  
 Changing Hearts—Quest for Pediatric Heart Transplants 280  
 Other Correlations—Genetics, Therapeutics, Nosology and Epidemiology 281  
 The Future: Dare to Try—No Star is Too High! 281

### 39. History of Pulmonary Embolism \_\_\_\_\_ 283

- Pathak LA, Pravin P, Parikh A*  
 Pathogenesis of Pulmonary Embolism 283  
 Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism 283  
 Management of Pulmonary Embolism 285

### 40. History of Stroke in Cardiac Patients \_\_\_\_\_ 289

- Patel A, Bharani A*  
 Hypertension and Stroke 291  
 Myocardial Infarction and Stroke 291  
 Heart Failure and Stroke 291  
 Mitral Stenosis and Stroke 291  
 Prosthetic Heart Valve and Stroke 292  
 Atrial Fibrillation and Stroke 292



Infective Endocarditis and Stroke	292
Paradoxical Embolism and Stroke	293
<b>41. Tobacco and Heart: A Historical Perspective</b>	<b>296</b>
<i>Mathur MR, Prabhakaran D</i>	
Historical Overview of Journey of Tobacco Across the World	297
Anti-Tobacco Movements and Sentiments—A Historical Snapshot	298
A Historical Synopsis of Establishment of Relationship between Tobacco Consumption and Cardiovascular Disease	299
Anti-Tobacco Policies—A Historical Synopsis	301
<b>42. History of Stress and Heart Disease Relationship</b>	<b>306</b>
<i>Bhat KSS, Vikranth V, Veeranna V</i>	
The Brain Heart Connection	306
<b>43. History of Cardiorenal Connectors</b>	<b>314</b>
<i>Hotchandani R, Khaira A</i>	
History of Cardiorenal Connectors	314
<b>44. History of Oxidative Stress and Cardiovascular Disease Protection</b>	<b>321</b>
<i>Prakash A, Agarwal SK</i>	
History	321
<b>45. History of Hormone Replacement Therapy and the Heart</b>	<b>325</b>
<i>Nath RK</i>	
Menopausal Symptoms	325
Discovery of Estrogen	326
Progesterone	326
Hormone Replacement Therapy	326
The Protective Effects of Estrogen on the Cardiovascular System	327
Hormone Replacement Therapy and Heart Disease	327
Hormone Replacement Therapy and Stroke	328
Hormone Replacement Therapy and Cancer	328
Hormone Replacement Therapy and Thromboembolic Disease	328
<b>46. Tuberculosis and Heart</b>	<b>330</b>
<i>Kumar S, Sindhe P</i>	
Tuberculosis of Heart	330
Tuberculosis and Myocardium	332
Tuberculosis and Atherosclerosis	333
Tuberculosis in Heart Transplant Recipients	333
<b>47. History of Cardiac Syncope</b>	<b>336</b>
<i>Das MK</i>	
Historical Landmarks	336
<b>48. History of Markers of Sudden Cardiac Death</b>	<b>340</b>
<i>Sinha AK</i>	
Arrhythmias During Sudden Cardiac Death	341
Pathophysiology of SCD—How do Noninvasive Tests Help Us	342
Markers of Sudden Cardiac Death	344
Scientists Reveal The Mystery of Sudden Cardiac Death	355
Markers of SCD in Individual Patients	355
Future Direction and My Point of View	356

<b>49. History of Women and Heart Disease</b>	<b>359</b>
<i>Vinod S, Tsering TP</i>	
Clinical Assessment and Chest Pain History	360
Enormity of Coronary Artery Disease in Women in Global Context	361
Gender Differences in Selecting the Appropriate Diagnostic Test	364
Medical Management for Coronary Artery Disease in Women	366
Final Interpretation	366
<b>50. History of Heart and Trans-Fat Relationship</b>	<b>370</b>
<i>Kumar A, Kaur H, Mohan V</i>	
Chemistry	370
Sources	370
Potential Molecular Mechanisms of Cardiovascular Effects of Trans-Fatty Acids	371
History of Trans-Fat Development and Progress in Food Industry	372
Trials Showing Increased Risk of Coronary Artery Disease with Intake of Trans-Fats	372
Ban on Trans-Fats	374
<b>51. Coronary Artery Disease and Homocysteine Relationship</b>	<b>380</b>
<i>Mohan PP, Deepesh R</i>	
Homocysteine Metabolism	380
<b>52. Savitri Satyawana: The First Described Cardiac Revival of the Vedic Times</b>	<b>390</b>
<i>Aggarwal KK</i>	
International Scenario In Brief (uptodate.com)	390
<b>53. History of Sildenafil: From Angina to Erectile Dysfunction</b>	<b>393</b>
<i>Shrivastava S, Sharma VK</i>	
History of Sildenafil	393
The Success Story of Sildenafil	394
Controversies	394
Expanding Uses beyond Treatment for Erectile Dysfunction	394
<b>54. Cardiocutaneous Diseases</b>	<b>396</b>
<i>Mendiratta V, Malik M</i>	
Genetic Disorders	396
Disorders of Keratinization	401
Autoimmune Diseases	402
Inherited Disorders of Elastin and Collagen	402
Disorders of Lipid Metabolism	403
Immunological and Infective Disorders	404
Inborn Errors of Metabolism	404
Infiltrative Disorders	405
<b>55. ARBs and CVD Protection</b>	<b>408</b>
<i>Ray S</i>	
History of Development of Angiotensin Receptor Blockers	408
Mode of Action of ARB	408
The Members of ARB Class	408
Role of ARB in Hypertension	409
ARB in Heart Failure	409
Post-MI Set-Up	409
Combination Therapy with ACE-I and ARB	409
ARB and Coronary Artery Disease	410
ARB and Stroke	410
ARB and Nephropathy	410

ARB and Diabetes 410

ARB and AF 410

## SECTION 2: NONINVASIVE CARDIOLOGY

### 56. Echocardiography: A History and Perspective 413

*Hage FG, Nanda NC*

The History of Ultrasound 413

Development of Clinical Cardiac Ultrasound: A-Mode and M-Mode Echocardiography 414

Two-Dimensional Echocardiography 417

Conventional Doppler Ultrasound 417

Color Doppler Ultrasound 419

Contrast Echocardiography 420

Transesophageal Echocardiography 423

Tissue Doppler and Speckle Tracking Imaging 423

Three-Dimensional Echocardiography 423

Perspective 425

### 57. History of Cardiac Imaging 432

*Krishna BA*

X-ray Imaging 432

Angiocardiology 432

Ultrasound Imaging 432

Two-Dimensional Echocardiography 433

Doppler Echocardiography 433

Intracardiac Intracoronary Ultrasound 433

Nuclear Imaging 433

Positron Emission Tomography 433

Computed Tomography 434

Magnetic Resonance Imaging 434

Fusion Imaging 434

### 58. History of Myocardial Contrast Echocardiography 436

*Chahal NS, Senior R*

Opacifying The Myocardium 436

Advances in Contrast Agents 436

Improving Microbubble Visualization 437

From Bench to Bedside 437

Quantifying Myocardial Perfusion 438

Safety of Ultrasound Contrast Agents 439

### 59. History of Stress Echocardiography 442

*Upadhyayula S, Kapur KK*

Historical Perspectives 442

Stress Echocardiography 443

Exercise-Induced Mitral Regurgitation 449

Real-Time Three-Dimensional Dobutamine Stress Echocardiography 456

Real-Time Myocardial Contrast Echocardiography + Three-Dimensional Stress Echocardiography 456

Two-Dimensional and Three-Dimensional Echocardiography in Non-Coronary Heart Diseases 456

Hemodynamic Two-Dimensional Stress Echocardiography 456

Preload Two-Dimensional Stress Echocardiography 457

Diastolic Two-Dimensional Stress Echocardiography 457

Evaluation of Cardiac Resynchronization Therapy Responders by Two-Dimensional Low-Dose Dobutamine Echocardiography + Myocardial Contrast Echocardiography 457

<b>60. Role of Echocardiography in Congenital Heart Disease—Catheter Interventions</b> .....	<b>463</b>
<i>Awasthy N, Shrivastava S</i>	
Role of Echocardiography in Congenital Heart Disease—Catheter Interventions	463
Evaluation of Atrial Septum by Transesophageal Echocardiography	465
Patent Foramen Ovale	466
Patent Ductus Arteriosus	469
Percutaneous Closure of Ductus Arteriosus	470
Valvuloplasty: Pulmonary and Aortic	471
Infundibular Stenosis	474
Left Ventricular Outflow Tract Obstruction	475
Coarctation of Aorta	476
Pericardiocentesis	478
<b>61. History of Fetal Cardiology</b> .....	<b>480</b>
<i>Chadha V, Kapoor N</i>	
The History of The Four-Chamber View	480
<b>62. Cardiac MRI: Present Status</b> .....	<b>494</b>
<i>Gulati P, Saini L</i>	
Applications of Cardiac MRI	495
Obstructive Disorders	497
Anatomic Disorders	498
Valvular Lesions	499
Cardiomyopathies	500
Cardiac Tumors	501
Neoplastic Diseases	505
Coronary MR Angiography	505
Transplanted Heart	506
History of MRI	508
<b>63. History of Nuclear Cardiology</b> .....	<b>509</b>
<i>Mahapatra GN</i>	
Various Nuclear Cardiology Procedures	510
<b>64. Telemedicine and Cardiology in India</b> .....	<b>539</b>
<i>Raju PK, Prasad SG</i>	
History	539
Indian Scenario	540
Burden in India—Coronary Heart Disease	541
Telemedicine as a Process	542
Methodologies	542
Application Software	543
Our Experiences	545
Obstacles and Challenges	551
<b>65. Echocardiographic Evaluation of Tricuspid and Pulmonic Valve</b> .....	<b>553</b>
<i>Malhotra P</i>	
Tricuspid Valve Anatomy	553
Transesophageal ECHO Examination of The Tricuspid Valve—Different Views	555
Abnormalities of the Tricuspid Valve	558
Tricuspid Stenosis	562
Pulmonary Regurgitation	565
Pulmonary Stenosis	568

Grading Pulmonic Stenosis	569
Historical Aspects of Echocardiography of Tricuspid and Pulmonary Valve	570

## SECTION 3: INTERVENTIONAL CARDIOLOGY

<b>66. History of Interventional Cardiology</b>	<b>575</b>
<i>Bhatia V, Kaul U</i>	
The Development of Right and Left Heart Catheterization	575
Unravelling the Coronary Vasculature	576
Moving into the Peripheral and Coronary Tree	577
The Stent Era—Stents and Other Devices	578
History of Some Other Devices and Concepts	579
<b>67. History of Saphenous Vein Grafts Intervention</b>	<b>581</b>
<i>Kumar V, Rastogi V, Seth A</i>	
Nature of Vein Graft Disease and its Pathophysiology	581
<b>68. History of Left Main Percutaneous Coronary Intervention</b>	<b>588</b>
<i>Mishra S, Bahl VK</i>	
<b>69. History and Future of Coronary Angioplasties by Radial Approach</b>	<b>594</b>
<i>Sengottuvelu G</i>	
History	594
Limitations of The Radial Approach	595
Future	595
<b>70. History of Cardiac Interventions and Future Directions</b>	<b>597</b>
<i>Upasani PT, Lal P</i>	
Cardiac Catheterization	597
Angioplasty and Related Catheter Interventions	599
High-Risk Angioplasty and Related Procedures	601
Adjunctive Equipment and Therapies Used in Angioplasty	601
The Discipline of Interventional Cardiology	602
Future Directions	602
A Note of Caution	603
<b>71. History of Catheter Ablation</b>	<b>605</b>
<i>Chen FC, Tester GA, Bisco SE, Gard JJ, Asirvatham SJ</i>	
History of The Prerequisites: Setting the Table	605
The His Bundle Electrogram	606
Surgery and Catheter Ablation	606
Supraventricular Tachycardia	606
Typical Atrial Flutter	607
Atrial Fibrillation	608
Ventricular Tachycardia	608
Past History	608
Future History	608
Summary—Back to the Future	609
<b>72. Cardiac Resynchronization Therapy</b>	<b>613</b>
<i>Rao BH</i>	
Pacing for Heart Failure	613
The Era of Randomized Trials	613
Do All Heart Failure Patients Need Cardiac Resynchronization Therapy-D?	616
Nonconventional Indications for Cardiac Resynchronization Therapy	616

- Patients without Overt Heart Failure 617
- Dyssynchrony and Cardiac Resynchronization Therapy 617
- The Issue of Response and Nonresponse 618
- Reasons For Non-response to Cardiac Resynchronization Therapy 618
- Etiology of Heart Failure 619
- Optimal Programming of Cardiac Resynchronization Therapy Parameters 619
- Future 620

### **73. History of Intravascular Ultrasound \_\_\_\_\_ 622**

- Garg N, Bhandari S*
- Development of Intravascular Ultrasound 622
  - Preliminary Studies 623
  - Therapeutic Studies of Intravascular Ultrasound 623

### **74. History of Intervention for Congenital Heart Disease \_\_\_\_\_ 625**

- Kohli V*
- History of Angiography 625
  - History of Balloon Atrial Septostomy 626
  - History of Valvuloplasty 627
  - History of Device Closure 628
  - History of Coil Closure 629
  - History of Stent Use 630
  - Timeline of Interventions of Congenital Heart Disease 630

### **75. Wide QRS Tachycardias Diagnosis and Management \_\_\_\_\_ 631**

- Singhal R, Jaswal A*
- Classification of Tachycardias with a Broad QRS Complex 631
  - Electrophysiology of Ventricular Tachycardia 631
  - Criteria to Differentiate Wide QRS Tachycardia 632
  - Etiology of Ventricular Tachycardia 632
  - Value of the Electrocardiogram during Sinus Rhythm 634
  - Value and Limitations of the Electrocardiogram in Broad QRS Tachycardia 635
  - Management of Wide QRS Tachycardia 635

### **76. History of Peripheral Vascular Interventions \_\_\_\_\_ 638**

- Rao SS, Khanna NN*
- Carotid Angioplasty 639
  - Advancement—The Age of Cerebral Protection 640
  - Renal Angioplasty 640
  - Angioplasty for Aortoiliac Occlusive Diseases 641
  - Angioplasty for Infrainguinal Peripheral Vascular Disease 641
  - Endovascular Repair of Aortic Aneurysm 641
  - History of IVC Filters 642

### **77. Intracardiac Echocardiography: Historical Perspective, Current Applications and Future Directions \_\_\_\_\_ 643**

- Katikireddy CK, Kort S*
- History 643
  - Types of Ice Catheters and Transducers 643
  - Ice Applications 645
  - Ice in the Pediatric Population 649
  - Accuracy of Ice 650
  - Complications of Ice 650
  - Limitations of Ice 650
  - Future Directions 650

---

---

**SECTION 4: CARDIAC SURGERY**

---

---

- 78. History and Advances in Cardiac Surgery** \_\_\_\_\_ **655**  
*Trehan N, Malhotra R, Dhir U*  
Coronary Artery Disease 655  
Percutaneous Valve Repair and Replacement 660  
Surgery for Heart Failure 661
- 79. History of Valvular Heart Surgery** \_\_\_\_\_ **667**  
*Yadava OP*  
Surgery for Mitral Stenosis 667  
Surgery for Aortic Stenosis 668  
Mitral Regurgitation 669  
Artificial Heart Valve 669  
Aortic Homograft 670  
Development of Tissue Valves 671  
Pulmonary and Tricuspid Valves—Poor Cousins 672  
Percutaneous Approaches to Valvular Heart Diseases 673  
Robotic Valve Surgery 673
- 80. History of Surgery for Ischemic Heart Disease** \_\_\_\_\_ **676**  
*Katariya K*  
Surgical Treatment of Ischemic Heart Disease: The First Era (Pre 1935) 677  
The Second (Pre Heart-Lung Machine) Era (1932-1954) 679  
Post Heart-Lung Machine Era (After 1954) 681
- 81. History of Robotically Assisted Cardiac Surgery** \_\_\_\_\_ **688**  
*Mishra YK, Collison SP*  
Historical Aspects of The Development of Current Robotic Technology 688  
Development of Robotic Cardiac Surgery 689  
Laparoscopic Surgery 689  
The Development of Telepresence Surgery 690  
Milestones in The Development of Robotic Cardiac Surgery 692  
Robotic Coronary Artery Bypass 693  
Mitral Valve Surgery 693  
Atrial Fibrillation Surgery 693  
Time Line of Salient Events in the Development of Robotic Cardiac Surgery 694  
Left Ventricular Lead Placement 695  
Congenital Heart Disease 695
- 82. History of Aortic Surgery** \_\_\_\_\_ **697**  
*Bhan A*  
Arterial Aneurysmal Disease 697  
Arterial Occlusive Disease 699  
Development of Vascular Grafts 700  
Development of Imaging 701  
Pioneers of Present Day Aortic Surgery 701  
Landmarks in Aortic Surgery 702
- 83. History of Heart Transplantation and Its Future** \_\_\_\_\_ **705**  
*Kohli V, Krishan K*  
Mechanical Circulatory Support 708  
The Future of Heart Transplant 708

<b>84. The History of Congenital Heart Surgery</b>	<b>710</b>
<i>Iyer KS</i>	
The Precardiopulmonary Bypass Era	710
The Era of Cardiopulmonary Bypass	712
Landmark Moments in the Development of Surgery	712
Origins of Congenital Heart Surgery in India	713

---

## SECTION 5: FUTURE OF CARDIOLOGY

---

<b>85. Future of Thrombolytics</b>	<b>717</b>
<i>Oliveros E, Dahya Z, Ishmael A, Peña C, Mehta S</i>	
History and Evolution of Fibrinolytic Therapy	717
Role of Thrombolytics for Acute Myocardial Infarction	717
Clinical Trials Relevant to the Development of Tenecteplase	719
Assent-3 Plus	722
Assent-4 PCI	722
Future Horizons of Thrombolytics Therapy	723
<b>86. Future of Thrombus, Thrombolytic Therapy and PCI in Cardiovascular Disorders in India</b>	<b>726</b>
<i>Iyengar SS</i>	
St Elevation Myocardial Infarction	726
Thrombolytic Therapy in Acute Ischemic Stroke	727
Thrombolytic Therapy in Acute Pulmonary Embolism	728
Thrombolytic Therapy in Other Situations	728
<b>87. Future of Balloon Valvotomy—Newer Aspects</b>	<b>730</b>
<i>Arora R</i>	
Mitral Stenosis	730
Tricuspid Stenosis	733
Pulmonary Valve Stenosis	734
Aortic Stenosis	735
Special Situations	736
Fetal Balloon Dilatation	736
<b>88. History of Stem Cell Therapy and its Future in Cardiovascular Diseases</b>	<b>739</b>
<i>Shah VK, Shalia KK</i>	
Preclinical Data Evidence towards Regeneration	739
Animal Experiments	740
Human Trials	742
Future Directions	746
Specific Set-Up Required for Clinical Cell Therapy to Ensure Quality Control and Safety	747
<b>89. Future of Heart Transplant in India</b>	<b>750</b>
<i>Shad S</i>	
Heart Transplant as the Definitive Treatment for Heart Failure	750
Indian Scenario	750
Essentials of Good Results of Heart Transplant	751
Factors Limiting Modern Therapies in India	751
Opportunities and the Way Forward	752

<i>Index</i>	<b>753</b>
--------------	------------